Detalhe da pesquisa
1.
Pregnancy, fertility concerns and fertility preservation procedures in a national study of French breast cancer survivors.
Reprod Biomed Online
; 44(6): 1031-1044, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35525718
2.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Lancet
; 393(10191): 2591-2598, 2019 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31178155
3.
Long-Term Gynecological Cancer Survivors in Côte d'Or: Health-Related Quality of Life and Living Conditions.
Oncologist
; 24(7): e490-e500, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30578310
4.
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
BMC Cancer
; 18(1): 526, 2018 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29728098
5.
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.
Breast Cancer Res
; 19(1): 98, 2017 Aug 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28830573
6.
[The anti-tumor immune response in breast cancer: Update and therapeutic perspectives]. / La réponse immunitaire anti-tumorale dans le cancer du sein : état des lieux et perspectives thérapeutiques.
Ann Pathol
; 37(1): 133-141, 2017 Feb.
Artigo
em Francês
| MEDLINE | ID: mdl-28159406
7.
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.
Breast Cancer Res
; 17: 56, 2015 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25888246
8.
Role of positron emission tomography for the monitoring of response to therapy in breast cancer.
Oncologist
; 20(2): 94-104, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25561512
9.
Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy.
BMC Cancer
; 15: 169, 2015 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-25879949
10.
Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
Anticancer Drugs
; 26(10): 1009-16, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26352219
11.
Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.
Future Oncol
; 11(16): 2283-97, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26260807
12.
¹8F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.
Eur J Nucl Med Mol Imaging
; 41(3): 428-37, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24196916
13.
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.
Eur J Nucl Med Mol Imaging
; 41(3): 416-27, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24258007
14.
HER2-positive breast cancer: ¹8F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
Eur J Nucl Med Mol Imaging
; 41(8): 1525-33, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24647576
15.
How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study.
Br J Clin Pharmacol
; 77(3): 498-508, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24283925
16.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Lancet Oncol
; 14(8): 741-8, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23764181
17.
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.
Lancet Oncol
; 14(1): 88-96, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23234763
18.
Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours.
BMC Cancer
; 13: 460, 2013 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-24099585
19.
Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.
BMC Cancer
; 13: 172, 2013 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-23547558
20.
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.
J Pathol
; 224(3): 389-400, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21437909